Crinetics Pharmaceuticals Inc
Closed
SectorHealthcare
83.93 0.16
Overview
Share price change
24h
Min
83.35
Max
83.81
Income | -5M -128M |
|---|---|
Sales | 6.8M 11M |
EPS | -1.23 |
Profit margin | -1,191.029 |
Employees | 594 |
EBITDA | -5M -127M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +2.44% upside |
Next Earnings | 4 Aug 2026 |
|---|
Market Cap | 4.5B 8.9B |
|---|---|
Previous open | 83.77 |
Previous close | 83.93 |
Crinetics Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Crinetics Pharmaceuticals Inc Forecast
Price Target
By TipRanks
2.44% upside
12 Months Forecast
Average 85.56 USD 2.44%
High 95 USD
Low 80 USD
Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
